 "Covaxin has started trials on children; it would be for children who are two years or older")
Bharat Biotech says that the final efficacy analysis of Covaxin shows it to be 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission.
This paves the way for Covaxin to get World Health Organisation's approval for its inclusion in the Emergency Use List of Covid-19 vaccines.
The company added that the analysis demonstrates Covaxin to be 93.4 per cent effective against
